晚期NSCLC患者血清EGFR基因突变状态的测定及意义

背景与目的小分子酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）对于表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的肺癌患者显示出良好的治疗效果。本研究旨在探讨晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者血清EGFR基因突变状态与EGFR-TKIs疗效的关系。方法检测80例一线口服EGFR-TKIs晚期NSCLC患者血清EGFR基因的突变状态,对患者进行长期随访并评价治疗效果。结果 80例患者血清EGFR基因突变27例（33.8%）,其中外显子19缺失突变12例...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 16; no. 6; pp. 303 - 307
Main Author 马玲 刘莉 张涛 单莉
Format Journal Article
LanguageChinese
Published 新疆医科大学附属肿瘤医院肺内一科, 新疆,830011 2013
Subjects
疗效
肺肿瘤
血清
表皮生长因子受体
酪氨酸激酶抑制剂
血清
Tyrosine kinase inhibitor
酪氨酸激酶抑制剂
Serum
Efficacy
肺肿瘤
表皮生长因子受体
Epidermal growth factor receptor
疗效
Lung neoplasms
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2013.06.06

Cover

More Information
Summary:背景与目的小分子酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）对于表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的肺癌患者显示出良好的治疗效果。本研究旨在探讨晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者血清EGFR基因突变状态与EGFR-TKIs疗效的关系。方法检测80例一线口服EGFR-TKIs晚期NSCLC患者血清EGFR基因的突变状态,对患者进行长期随访并评价治疗效果。结果 80例患者血清EGFR基因突变27例（33.8%）,其中外显子19缺失突变12例（44.4%）,外显子21点突变15例（55.6%）;血清EGFR基因突变患者的有效率（55.6%,15/27）高于野生型患者（17.0%,9/53）,差异具有统计学意义（χ2=0.370,P〈0.001）;血清EGFR基因突变患者中位无进展生存时间（progress free survival,PFS）明显长于野生型患者（9.8个月vs5.7个月,P=0.014）。结论血清EGFR基因突变患者一线口服EGFR-TKIs的疗效优于野生型患者,血清EGFR基因状态可为EGFR-TKIs的一线治疗提供有效依据。
Bibliography:Ling MA, Li LIU, Tao ZHANG, Li SHAN（ Department of Medical Oncology, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China ）
Lung neoplasms; Serum; Epidermal growth factor receptor; Tyrosine kinase inhibitor; Efficacy
Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） has shown a high response rate in the treatment of lung cancer in patients with （EGFR） mutation. The aim of this study is to evaluate the relationship between EGFR mutation status in serum and predicting benefit from EGFR-TKIs therapy in patients with advanced non-small cell lung cancer （NSCLC）. Methods We examined EGFR mutation status in serum of 80 patients with advanced, EGFR-TKIs given as first-line therapy NSCLC. All patients were received long-term follow-up, and the drug efficacy were observed and evaluated. Results The EGFR mutation in serum was detected in 33.8% （27/80） of NSCLC patients examined, in which exon 19 deletion mutation was present at a frequency of 44.4% （
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2013.06.06